Connect your agent to akta.pro and build company lists like this across sectors and geos.
Track workforce reductions across 15 US biotech companies during July–September 2026, from clinical-stage therapy developers to established biopharma businesses. Compare headcount cuts, clinical setbacks, portfolio shifts and restructuring decisions.
— 3 companies cut 60% or more of staff — TScan Therapeutics cut about 75%, Lisata Therapeutics 72% and aTyr Pharma 60%, all clinical-stage companies conserving cash for pipeline programs.
— 2 cuts followed Phase 3 trial setbacks — TScan paused its Phase 3 ALLOHA-2 trial for lack of funding, and Kolon TissueGene cut 37 jobs after its Phase 3 osteoarthritis trial missed primary endpoints.
— 3 cuts of 90 or more jobs came from restructurings — Sanofi cut 229 Blueprint Medicines jobs, Genentech 103 and Emergent BioSolutions 90.
Companies ranked 1515 companies included in this ranking
Highest relevance score 6.2 of 10Emergent BioSolutions — highest scored entry
Cuts of 60% or more of staff 3 of 15TScan Therapeutics, Lisata Therapeutics and aTyr Pharma
Coverage: United States, companies Filter: Negative sentiment Window: Jul 1, 2026 – Sep 30, 2026 Ranked by: Incident relevance Source: akta.pro News Signals Compiled: Sep 30, 2026| # | Company name | Firmographics | Funding & investors | What company does | What happened & why | Sources |
|---|---|---|---|---|---|---|
| 01 | Emergent BioSolutions emergentbiosolutions.com Elevated | Founded 1997 Gaithersburg, MD USA | $436M Last raise 2026 | Emergent BioSolutions (NYSE: EBS) is a public biodefense and specialty life sciences company that develops, manufactures, and delivers medical countermeasures for biological threats and opioid overdose emergencies to government agencies, healthcare providers, and commercial customers in more than 20 countries. Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) |
Emergent BioSolutions announced in August 2026 workforce reductions affecting 90 employees as part of a restructuring that targets about 40 million dollars in annualized savings and closes two Maryland laboratories. Why The coverage says the restructuring followed a 191.3 million dollar non-cash impairment charge reported with second-quarter results. |
3 sources · 3 outlets |
| 02 | Cellares cellares.com Elevated | Founded 2017 South San Francisco, CA USA | $682M Last raise 2026 | Cellares is a cell therapy contract development and manufacturing company that uses its automated Cell Shuttle platform and integrated quality-control technology to manufacture cell therapies for biotechnology and pharmaceutical partners. Cell Therapy CDMO |
Cellares filed a WARN notice on 21 August 2026 to terminate 100 employees at its South San Francisco facility by 20 October, two months after a 327 million dollar Series D round. Why The CEO said the loss of a key pharmaceutical customer that ended its partnership was the primary driver of the restructuring. |
3 sources · 3 outlets |
| 03 | TScan Therapeutics tscan.com Elevated | Founded 2018 Waltham, MA USA | $410M Last raise 2024 | TScan Therapeutics is a clinical-stage biotechnology company developing T-cell receptor (TCR)-engineered T-cell therapies for cancer. Its programs include treatments for blood cancers and in vivo cell engineering approaches for solid tumors. CAR-T & TCR-T Therapies |
TScan Therapeutics announced on 2 September 2026 a roughly 75% workforce reduction, paused enrollment in its Phase 3 ALLOHA-2 trial and pivoted to in vivo solid tumor therapies, and its shares fell about 32%. Why The coverage says the company lacked the funds to finish the trial, with 100.2 million dollars in cash against a 30 million dollar quarterly burn. |
3 sources · 2 outlets |
| 04 | Enanta Pharmaceuticals enanta.com Elevated | Founded 1995 Watertown, MA USA | $159M Last raise 2025 | Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule therapeutics for viral infections and immunology, generating royalty revenue from AbbVie's hepatitis C treatments while advancing a pipeline in RSV, HBV, and inflammatory diseases. Infectious Disease & Antimicrobials Pharmaceuticals |
Enanta Pharmaceuticals laid off 37 employees, reported on 29 September 2026, from a workforce of 120 as of 30 September 2025. Why The company cited a fiscal year-end evaluation of resources to right-size operations. |
1 source |
| 05 | Aurora Therapeutics auroratherapeutics.io Elevated | Founded 2026 Cambridge, MA USA | $16M Last raise 2026 | Aurora Therapeutics is a clinical-stage biotech developing personalized CRISPR gene editing therapies for rare genetic diseases, starting with phenylketonuria. Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) |
Aurora Therapeutics, a custom gene-editing startup, abandoned its lead program and cut staff in August 2026, seven months after launch, with no layoff count disclosed. Why The coverage suggests the company was undermined by a larger competitor, Beam Therapeutics, advancing its own custom gene editors. |
2 sources · 2 outlets |
| 06 | Blueprint Medicines blueprintmedicines.com Elevated | Founded 2015 Cambridge, MA USA | $3.62B Last raise 2022 | Blueprint Medicines, a Sanofi company, develops precision kinase-targeted therapies for systemic mastocytosis, PDGFRA-mutant GIST, and other rare allergic/inflammatory and oncology diseases. Mast Cell Disorders Specialty Care |
Sanofi will lay off 229 employees from its acquired Blueprint Medicines operations and close two Cambridge, Massachusetts offices, with the cuts disclosed in a WARN notice and running from October 2026 to June 2027. Why The coverage describes the cuts as post-acquisition integration, with remaining staff consolidating onto Sanofi's existing campus. |
2 sources · 2 outlets |
| 07 | Aura Biosciences aurabiosciences.com Elevated | Founded 2009 Boston, MA USA | $756M Last raise 2026 | Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugate (VDC) therapies, with lead candidate bel-sar in a Phase 3 trial for early choroidal melanoma and additional programs in bladder cancer and other solid tumors, targeting rare ocular and urologic oncology indications with no approved drug therapies. Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) |
Aura Biosciences laid off about 20% of its workforce, roughly 23 employees, in August 2026 and reshuffled its leadership to concentrate on eye cancer indications. Why The coverage says the restructuring focuses resources on its lead eye cancer drug and extends the cash runway into 2029, after a 45.6 million dollar second-quarter net loss. |
2 sources · 2 outlets |
| 08 | aTyr Pharma atyrpharma.com Elevated | Founded 2005 San Diego, CA USA | $433M Last raise 2025 | aTyr Pharma is a clinical-stage biotherapeutics company developing protein therapeutics derived from tRNA synthetase biology for fibrosis and inflammation, with lead candidate efzofitimod in development for interstitial lung diseases including pulmonary sarcoidosis and SSc-ILD. Recombinant Protein Therapeutics (enzymes, hormones, growth factors) |
aTyr Pharma announced in August 2026 a roughly 60% workforce reduction to focus on its efzofitimod lung disease program and extend its cash runway into late 2028. Why The coverage says the cuts conserve resources for a second Phase 3 trial while the company awaits FDA feedback on its sarcoidosis study protocol. |
2 sources · 2 outlets |
| 09 | Lisata Therapeutics lisata.com Elevated | Founded 2022 Basking Ridge USA | $391M Last raise 2026 | Lisata Therapeutics is a clinical-stage pharmaceutical company developing therapies for solid tumors. Its lead investigational peptide, certepetide, is designed to improve the penetration and effectiveness of anticancer drugs inside tumors. Lead Optimization & Preclinical Candidate Selection |
Lisata Therapeutics laid off about 72% of its workforce, around 15 staff including its chief medical officer, in early August 2026 after its planned acquisition by Kuva Labs collapsed. Why The coverage ties the cuts to the failed merger and says Lisata sued Kuva Labs in Delaware seeking damages and a 2 million dollar termination fee. |
2 sources · 2 outlets |
| 10 | TissueGene tissuegene.com Elevated | Founded 1999 Rockville, MD USA | $213M Last raise 2025 | Kolon TissueGene is a clinical-stage biopharmaceutical company developing first-in-class allogeneic cell and gene therapies, led by TG-C for knee osteoarthritis, for patients with musculoskeletal and degenerative orthopedic disorders. Cartilage, Bone & Musculoskeletal Regeneration |
Kolon TissueGene is laying off 37 employees at its Maryland headquarters in August 2026 after a Phase 3 trial of its osteoarthritis therapy TG-C missed its primary endpoints. Why The company described the cut as part of a broader operational realignment while it awaits results from a second Phase 3 trial in October. |
1 source |
| 11 | Ensoma ensoma.com Elevated | Founded 2020 Boston, MA USA | $258M Last raise 2025 | Ensoma is a Boston-based clinical-stage biotech developing in vivo HSC engineering therapies via its Engenious Platform, which combines high-capacity VLPs with CRISPR-Cas and base editing to deliver one-time gene therapies for X-CGD, sickle cell disease, and solid tumors. Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) |
Ensoma conducted another round of layoffs in August 2026 and paused preclinical programs to concentrate on its lead gene therapy EN-374, after halving its workforce the previous November. Why The coverage says the company is focusing resources on clinical validation of its lead program until more funding is secured. |
1 source |
| 12 | BioCryst Pharmaceuticals biocryst.com Elevated | Founded 1986 Durham, NC USA | $1.79B Last raise 2023 | BioCryst Pharmaceuticals is a commercial-stage biotech that discovers and commercializes small-molecule and injectable protein therapeutics for rare diseases, anchored by ORLADEYO, the first oral prophylactic therapy for hereditary angioedema, serving HAE patients globally through direct US sales and international licensing partnerships. Pulmonology & Allergy Specialty Pharmaceuticals |
BioCryst Pharmaceuticals is closing its Hoover, Alabama facility and laying off 47 workers, according to a WARN notice issued in early August 2026. Why The coverage says the company announced in June it would discontinue internal discovery programs and shut its Birmingham Discovery Center of Excellence. |
1 source |
| 13 | Amgen amgen.com Elevated | Founded 1980 Thousand Oaks, CA USA | $28.50B Last raise 2022 | Amgen is a global independent biotechnology company headquartered in Thousand Oaks, California, that discovers, develops, manufactures, and commercializes biologic medicines across cardiovascular, oncology, inflammation, bone health, and rare disease therapeutic areas, serving millions of patients in approximately 100 countries worldwide. Specialty Care Pharmaceuticals |
Amgen laid off about 40 employees, around 0.1% of its global workforce, in July 2026, and confirmed the cuts. Why The company said the cuts align with organizational changes tied to its strategic objectives, amid pipeline setbacks and regulatory scrutiny of its rare disease drug Tavneos. |
1 source |
| 14 | Genentech gene.com Elevated | Founded 1976 South San Francisco, CA USA | $35M 1980 IPO proceeds · historical | Genentech is a US-based biotechnology subsidiary of Roche Holding AG that develops and commercializes biologic and small-molecule medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic disease, serving patients, hospitals, and specialty pharmacies worldwide. Specialty Care Pharmaceuticals |
Genentech will lay off 103 employees by the end of July 2026, bringing its California layoffs to nearly 450 since July 2025. Why The coverage attributes the cuts to ongoing restructuring to align capabilities with core therapeutic areas. |
1 source |
| 15 | Sionna Therapeutics sionnatx.com Elevated | Founded 2019 Waltham, MA USA | $530M Net private equity + IPO proceeds | Sionna Therapeutics is a clinical-stage biotechnology company developing NBD1 stabilizer-based therapies for cystic fibrosis. Cystic Fibrosis Drug Development |
Sionna approved a restructuring on September 9, 2026 to reduce its workforce by approximately 46%, following disappointing Phase 2a results for SION-719. Why The company aimed to extend its cash runway and focus on its SION-451 and SION-2222 dual-combination development program. |
1 source |
This dashboard covers US biotechnology and biopharma companies in akta.pro's Healthcare & Life Sciences sector, from clinical-stage drug developers to cell therapy manufacturers and large pharmaceutical groups. Layoffs matter here because pipelines depend on trial results, partner contracts and funding runways.
The ranked companies span oncology, gene and cell therapy, infectious disease and manufacturing, so the codes below reflect several sub-industries rather than one.
This section describes the industry classification of the ranked companies, not the Workforce Reductions signal category the dashboard tracks.
NAICS and SIC are global standard industry classifications, shown as returned by akta.pro Company Data for the listed companies. The internal taxonomy is akta.pro's own industry tree: each code links to its akta.pro industry page, and the signal categories this page filters on are listed in the Methodology below.